- ES
- EN
Start of main content
Life and Matter Sciences International Symposium November 3-4, 2016 Madrid
Venue: Fundación Ramón Areces, Vitruvio, 5. 28006. Madrid
Limited capacity
Organized by:
Fundación Ramón Areces
In cooperation with:
CIBERER
Coordinator/s:
Isabel Varela-NietoInstituto de Investigaciones Biomédicas "Alberto Sols" (IIBM). CSIC-UAM-CIBERER. Madrid
Deputy Coordinators:
Joaquín DopazoCentro de Investigación Príncipe Felipe-BiER platform. CIBERER. Valencia. Spain
José Mª MillánInstituto de Investigación Sanitaria Hospital La Fe. CIBERER. Valencia. Spain
Francisca SánchezFacultad de Ciencias. Universidad de Málaga. CIBERER. Spain
Biomedical research is the basis for providing new tools for the diagnosis and treatment of rare diseases. There are around eight thousand rare diseases, each of them with a maximal prevalence of one case per 2,000 inhabitants. In this context, the availability of homogenous, detailed scientific information, and accessible to the patient, is essential to define the spectrum of action of basic researchers and clinicians. This is the service that Orphanet offers in the field of rare diseases. Open access and documentation initiatives, especially those that expand the field and go to the patient as a Europe PMC, made valuable contributions to the advancement of public awareness. In parallel, the role of biobanks in the storage of samples from rare disease patients increases the opportunities for genetic research.
The development and study of animal models of human diseases has a central role in the field of rare diseases. The characterization of the genome of different species and the phenotyping of rare disease animal models contributes to the study of the physiopathology, the understanding of the molecular mechanisms underlying, to identify diagnostic criteria and to the evaluation and refinement of new therapies. Since the majority of rare diseases present a complex syndromic nature, it is necessary to offer a range of specialized tests able to evaluate the function of different organs.
The generation of genome, transcriptome and proteome data contributes to clarify the biological processes and mechanisms of disease, as well as to the clinical and pharmacogenetic evaluation of patients. Massive analysis of these data together with the increasingly growing genomic Big Data already existent in databases, in particular in the case of rare diseases, facilitates valuable information that requires the development and use of programs and bioinformatic platforms as ELIXIR.
This symposium seeks to the interaction between members of national and international platforms of information, biobanks, bioinformatics and phenotyping of genetically engineered mice. The evolution of technology and of the resources available in these areas is on-going and accelerated, so the symposium offers a unique educational opportunity for early stage researchers.
9:30
Federico Mayor Zaragoza
Chairman of the Scientific Council. Fundación Ramón Areces.
José María Medina
Deputy Chairman fo the Scientific Council. Fundación Ramón Areces.
Isabel Varela-Nieto
Coordinator
Joaquín Dopazo
José Mª Millán
Francisca Sánchez
Deputy Coordinators.
Chairwoman:
Silvia Murillo-Cuesta
Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM). CSIC-UAM- CIBERER. Madrid. Spain.
10:00
Martin Hrabě de Angelis
Institute of Experimental Genetics. Múnich. Germany.
11:00
Jesús Ruberte
Center for Animal Biotechnology and Gene Therapy. Universidad Autónoma de Barcelona. CIBERDEM. Spain
11:30
Break
12:00
Karen Svenson
Jackson Laboratories. USA.
13:00
Lluís Montoliu
Centro Nacional de Biotecnología (CNB). CSIC-CIBERER. Madrid. Spain.
13:30
Isabel Varela-Nieto
Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM). CSIC-UAM-CIBERER. Madrid. Spain.
14:00
Break
Chairwoman:
Francisca Sánchez
Facultad de Ciencias. Universidad de Málaga. CIBERER. Spain.
16:00
Ángel Carracedo
Universidad de Santiago de Compostela. CIBERER. Spain.
16:30
Concha Gil
Parque Científico y Facultad de Farmacia. Universidad Complutense. Madrid. Spain.
17:00
Manuel Corpas
Wellcome Trust Sanger Institute. Cambridge. UK.
17:30
Juan Antonio García Ranea
Universidad de Málaga. CIBERER. Spain.
Chairman:
José Mª Millán
Instituto de Investigación Sanitaria Hospital La Fe. CIBERER. Valencia. Spain.
9:30
Martín Arlés
Orphanet Rare disease platform. Paris. France.
10:00
Jo McEntyre
European Bioinformatics Institute. EMBL-EBI. European Molecular Biology Laboratory.
Wellcome Trust Genome Campus. Cambridge. UK.
10:30
Luca Sangiorgi
Medical Genetic Department. Rizzoli Orthopaedic Institute. Bologna. Italy.
11:00
Manuel Morente
Unidad de Banco de Tumores. Centro Nacional de Investigaciones Oncológicas (CNIO). Instituto de Salud Carlos III. Madrid. Spain.
11:30
Break
Chairman:
Lluís Montoliu
Centro Nacional de Biotecnología (CNB). CSIC-CIBERER. Madrid. Spain.
12:00
Joaquín Dopazo
Centro de Investigación Príncipe Felipe-BiER platform. CIBERER e INB-ELIXIR-es. Valencia. Spain.
12:30
Marco Roos
Biosemantics group, Human Genetics Department. Leiden University Medical Centre. The Netherlands.
13:00
Augusto Rendon
Genomics England. Queen Mary University of London. UK.
13:30
Activities related
Projects related
News related
Publications related
Panel Discussion Biomateriales: Impacto Social Madrid, Monday, 30 January 2023, 17:00 hours
Panel Discussion Mundo de las prótesis, los nuevos materiales, sus complicaciones y su futuro Madrid , Lunes, 8 de abril 2024. 17.00 horas
Session Situación actual de las Enfermedades Raras en España Madrid, Martes, 23 de abril de 2024, 10:00 horas

La Fundación Ramón Areces refuerza su compromiso con las enfermedades raras
Published on 04/23/2024
End of main content